Boehringer Ingelheim Launches Venture Capital Fund

Boehringer Ingelheim (Ingelheim, Germany) says it has launched a corporate venture capital fund, Boehringer Ingelheim Venture Fund (BIVF), which aims to invest in biotechnology and start-up companies that provide groundbreaking therapeutic approaches and technologies to help drive innovation in medical science. These will include new therapeutic concepts including stem cells and RNA silencing, as well as new-generation vaccines, new-generation protein or antibody technologies, new molecular targets, and/or first-in-class lead compounds, as well as disease-related...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers